Zietz B, Reber T, Oertel M, Glück T, Schölmerich J, Straub R H
Department of Internal Medicine I, University Medical Center Regensburg, Germany.
J Rheumatol. 2000 Apr;27(4):911-8.
To investigate adrenocorticotropin, androstenedione (ASD), cortisol, or dehydroepiandrosterone sulfate (DHEAS) before and during a corticotropin releasing hormone (hCRH) test in patients with moderately active systemic lupus erythematosus (SLE) undergoing low dose longterm glucocorticoid therapy, and to examine these hormones in relation to interleukin 6 (IL-6) or tumor necrosis factor (TNF).
Serum levels of hormones and cytokines were measured before and during an hCRH test. The results of 12 patients with SLE were compared to 12 healthy subjects (HS) and 12 healthy subjects given prior short term prednisolone (HS+P).
Baseline and stimulated serum ASD, cortisol, and DHEAS were lower in patients with SLE vs. HS (p<0.005), but baseline and stimulated plasma adrenocorticotropin was normal in SLE. In SLE, but not in HS+P or HS, baseline and stimulated DHEAS was low in relation to cortisol or ASD (i.e., shift from DHEAS to cortisol or ASD). In patients with SLE, baseline and stimulated serum levels of adrenal hormones were lower in relation to IL-6 or TNF compared to HS or HS+P (p< 0.001). In contrast, in SLE patients, the baseline and stimulated pituitary hormone adrenocorticotropin was normal in relation to these cytokines.
We found marked adrenal insufficiency and a shift in steroidogenesis to cortisol in patients with SLE, but a completely normal pituitary function (in absolute values and in relation to IL-6 or TNF). This may depend in part on prior longterm glucocorticoid therapy and changes of steroidogenesis due to cytokines. The situation in patients with SLE was not mimicked by high dose short term prednisolone in healthy subjects. Further longitudinal studies in untreated patients are needed to investigate the endocrine-immune interplay and its consequences during the course of SLE.
研究中度活动的系统性红斑狼疮(SLE)患者在接受低剂量长期糖皮质激素治疗期间及促肾上腺皮质激素释放激素(hCRH)试验前后的促肾上腺皮质激素、雄烯二酮(ASD)、皮质醇或硫酸脱氢表雄酮(DHEAS),并检测这些激素与白细胞介素6(IL-6)或肿瘤坏死因子(TNF)的关系。
在hCRH试验前后测量激素和细胞因子的血清水平。将12例SLE患者的结果与12名健康受试者(HS)和12名预先给予短期泼尼松龙的健康受试者(HS+P)进行比较。
与HS相比,SLE患者的基线和刺激后血清ASD、皮质醇和DHEAS较低(p<0.005),但SLE患者的基线和刺激后血浆促肾上腺皮质激素正常。在SLE患者中,与皮质醇或ASD相关的基线和刺激后DHEAS较低(即从DHEAS向皮质醇或ASD转变),但在HS+P或HS中并非如此。与HS或HS+P相比,SLE患者的基线和刺激后肾上腺激素血清水平与IL-6或TNF相关较低(p<0.001)。相反,在SLE患者中,基线和刺激后垂体激素促肾上腺皮质激素与这些细胞因子相关正常。
我们发现SLE患者存在明显的肾上腺功能不全,类固醇生成向皮质醇转变,但垂体功能完全正常(绝对值以及与IL-6或TNF相关)。这可能部分取决于先前的长期糖皮质激素治疗以及细胞因子导致的类固醇生成变化。健康受试者中高剂量短期泼尼松龙并未模拟SLE患者的情况。需要对未治疗的患者进行进一步的纵向研究,以调查SLE病程中的内分泌-免疫相互作用及其后果。